Imiquimod Upregulates the Opioid Growth Factor Receptor to Inhibit Cell Proliferation Independent of Immune Function

@article{Zagon2008ImiquimodUT,
  title={Imiquimod Upregulates the Opioid Growth Factor Receptor to Inhibit Cell Proliferation Independent of Immune Function},
  author={Ian S. Zagon and Renee Nicole Donahue and Moshe Rogosnitzky and Patricia J. McLaughlin},
  journal={Experimental Biology and Medicine},
  year={2008},
  volume={233},
  pages={968 - 979}
}
The imidazoquinoline compounds imiquimod and resiquimod are low-molecular-weight immune response modifiers that have potent anti-viral and anti-tumor properties. The mechanism by which they exert their effects remains unclear. Using pancreatic and colorectal cancer cells, as well as squamous carcinoma cells of the head and neck in tissue culture, which eliminated the immune system and toll-like receptors, we show that the imidazoquinolines upregulate the Opioid Growth Factor receptor (OGFr… Expand
Inhibition of DNA synthesis in mouse epidermis by topical imiquimod is dependent on opioid receptors
TLDR
The results suggest that the target of imiquimod on DNA synthesis is dependent on an opioid receptor-mediated pathway, and infers that imiquIMod is reliant on the OGF–OGFr axis for modulating cell proliferation. Expand
Imiquimod: The biochemical mechanisms of immunomodulatory and anti-inflammatory activity
TLDR
Detailed analysis of the published data suggests that the biological activity of imiquimod can not be explained only by its interaction with TLR7, and certain evidence exists that imquimod directly interacts with adenosine receptors and other molecules that regulate synthesis of cyclicAdenosine monophosphate. Expand
The opioid growth factor-opioid growth factor receptor axis regulates cell proliferation of human hepatocellular cancer.
TLDR
These data are the first to report that the OGF-OGFr system is a native biological regulator of cell proliferation in HCC, and may provide important insight in designing treatment strategies for this deadly disease. Expand
Under-expression of the opioid growth factor receptor promotes progression of human ovarian cancer
TLDR
Data demonstrate the critical nature of the OGF–OGFr axis as a determinant of the progression of human ovarian cancer, and suggest that attenuation of this system has an important bearing on the survival of these patients. Expand
Opioid growth factor-opioid growth factor receptor axis is a physiological determinant of cell proliferation in diverse human cancers.
TLDR
The OGF-OGFr axis, a physiological determinant of cell-proliferative activity, is a ubiquitous feature of human cancer cells and its identification may be important in understanding the pathophysiology of neoplasia, and in designing treatment modalities that utilize the body's own chemistry. Expand
Cell proliferation of human ovarian cancer is regulated by the opioid growth factor-opioid growth factor receptor axis.
TLDR
These data are the first to report that the OGF-OGFr system is a native biological regulator of cell proliferation in human ovarian cancer. Expand
Low-dose naltrexone targets the opioid growth factor–opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture model
TLDR
It is demonstrated at the molecular level that the OGF–OGFr axis is a common pathway that is essential for the regulation of cell proliferation by NTX. Expand
Overexpression of OGFr Downregulates Ovarian Cancer Cell Proliferation in Vitro and Inhibits Tumorigenesis
TLDR
Preclinical evidence demonstrates that OGFr expression is a molecular determinant of ovarian cancer progression, and has important relevance to understanding the pathogenesis and treatment of this deadly disease. Expand
In vitro and in vivo growth inhibition of prostate cancer by the small molecule imiquimod.
TLDR
In vitro and in vivo antitumor effect of the small molecule imiquimod, also known as a TLR7 agonist, against prostate cancer is examined to indicate that imiquIMod can be an alternative therapeutic for locally generated prostate cancer. Expand
The role of opioid growth factor in enhancing the success of trabeculectomy
TLDR
Estimation of the role of OGF and OGFr in the modulation of cell proliferation of rabbit TCFs (RTCFs) in vitro as well as in vivo and the mechanism of action of the OGF/OGFr axis on the survival of RTCFs revealed that OGF works to inhibit proliferation of R TCFs in a dose dependent manner. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 35 REFERENCES
Imiquimod Treatment Induces Expression of Opioid Growth Factor Receptor
TLDR
In addition to its immunomodulatory and antiproliferative activity, opioid growth factor receptor seems to have a prognostic significance in basal cell carcinoma patients. Expand
Antitumor effects of imidazoquinolines in urothelial cell carcinoma of the bladder.
TLDR
Imidazoquinolines have potent direct activity against bladder cancer cells by decreasing cell viability and inducing apoptosis and cytokine production, and in vivo data suggest antitumor effects in an orthotopic bladder cancer mouse model. Expand
Imiquimod: modes of action
  • D. Sauder
  • Medicine
  • The British journal of dermatology
  • 2003
TLDR
New developments and applications of imiquimod are presented to present new developments of the immunomodulating agent that was approved in 1997 by the U.S. Food and Drugs Administration for treating external genital and perianal warts. Expand
Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential
  • M. Stanley
  • Medicine
  • Clinical and experimental dermatology
  • 2002
TLDR
Imiquimod has been shown to be significantly more effective than placebo in clearing genital warts, and mechanism of action studies indicate that this is related to the ability to generate proinflammatory cytokines and a Th1 response. Expand
Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod.
TLDR
Imiquimod has the potential to induce apoptosis in skin cancer cells, possibly by circumventing mechanisms developed by malignant tumors to resist apoptotic signals. Expand
Opioid growth factor regulates the cell cycle of human neoplasias.
TLDR
The results indicate that OGF action is directed at the G0/G1 phase, but interruption of OGF-OGFr interfacing has widespread repercussions on the cell cycle, suggesting a requisite escorting of the growth peptide and its receptor through thecell cycle. Expand
Imiquimod applied topically: a novel immune response modifier and new class of drug.
TLDR
Imiquimod is expected to be effective where exogenous IFN-alpha has shown utility and where enhancement of cell-mediated immunity is needed and will likely lead to benefits in several other chronic virus infections and tumors of the skin. Expand
Imiquimod and resiquimod as novel immunomodulators.
TLDR
The imidazoquinolinamines imquimod and resiquimod have demonstrated potency as inducers of IFN-alpha and other cytokines both in vitro and in vivo and may find roles in the therapy of cancers and as vaccine adjuvants. Expand
The opioid growth factor (OGF)-OGF receptor axis uses the p16 pathway to inhibit head and neck cancer.
TLDR
The data are the first to reveal that the target of cell proliferative inhibitory action of OGF in human HNSCC is a cyclin-dependent kinase inhibitory pathway, and this may be useful in the diagnosis and treatment of H NSCC. Expand
Overexpression of the opioid growth factor receptor downregulates cell proliferation of human squamous carcinoma cells of the head and neck.
TLDR
Data indicate that the OGF receptor is integral to cell replication of SCCHN, and support treatment modalities that amplify OGFr in order to decrease the growth of these neoplasias. Expand
...
1
2
3
4
...